Here are three things to know.
- Mydayis is intended to treat ADHD symptoms in patients thirteen years or older.
- The once-daily drug features the same active ingredients as Shire’s popular ADHD drug Adderall, but is formulated to last up to 16 hours, according to Reuters.
- Shire plans to launch Mydayis in the third quarter of this year.
More articles on supply chain:
Global drug sales forecast falls for 1st time in decade
Stryker to acquire imaging technology company for $701M
SCOTUS decision reduces drugmakers’ product liability
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
